Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

FDA Approves Neoadjuvant Nivolumab/Chemo for Resectable NSCLC

March 4th 2022

The FDA has approved nivolumab plus platinum-doublet chemotherapy for adult patients with resectable non–small cell lung cancer in the neoadjuvant setting.

Dr. Iams on the Key Implications of the ADAURA Trial in NSCLC

March 1st 2022

Wade T. Iams, MD, discusses the key implications of the phase 3 ADAURA trial in non–small cell lung cancer.

FDA Grants Priority Review to Neoadjuvant Nivolumab/Chemo for Resectable NSCLC

February 28th 2022

The FDA has granted priority review to a supplemental biologics license application for the combination of nivolumab and chemotherapy in the neoadjuvant treatment of patients with resectable non–small cell lung cancer.

Broad Panel Testing Is the First Step in Tailoring Treatment Throughout Lung Cancer

February 22nd 2022

Jacob Sands, MD, discusses biomarker testing in lung cancer, the utilization of neoadjuvant and frontline immunotherapy, and targeted therapy advances in non–small cell lung cancer.

Dr. Leal on the Utilization of PD-1/PD-L1 Inhibitor Monotherapy in Lung Cancer

February 21st 2022

Ticiana Leal, MD, discusses the utilization of PD-1 and PD-L1 inhibitor monotherapy in lung cancer.

Tepotinib Approved in Europe for METex14-Altered Advanced NSCLC

February 21st 2022

The European Commission has approved tepotinib for use as a single agent in adult patients with advanced non–small cell lung cancer harboring METex14 skipping alterations who require systemic therapy after prior treatment with immunotherapy and/or platinum-based chemotherapy.

SCLC: Future Therapies and Advice to Community Oncologists

February 21st 2022

Drs Carl M. Gay and Jared Weiss highlight several novel strategies that show promise in optimizing treatment for patients with small cell lung cancer and respond to questions from community oncologists who manage treatment for patients with lung cancer.

FDA Approval Sought for Adagrasib in Previously Treated KRAS G12C–Mutated NSCLC

February 15th 2022

The FDA has accepted a new drug application for the use of adagrasib in the treatment of patients with non–small cell lung cancer whose tumors harbor a KRAS G12C mutation and who have previously received at least 1 prior systemic therapy.

FDA Accepts NDA for Poziotinib in HER2 Exon 20–Mutated NSCLC

February 14th 2022

The FDA has accepted for review a new drug application for poziotinib in patients with previously treated locally advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations.

Future Perspectives in EGFR+ NSCLC

February 14th 2022

Global perspectives on the future management of EGFR+ non–small cell lung cancer given recent advances in the treatment paradigm.

EGFR+ Advanced NSCLC Resistant to Frontline TKIs: C797S Mutation

February 14th 2022

Expert perspectives on the management of C797S-mutated non–small cell lung cancer following failure of frontline TKIs.

Treatment Options for Relapsed Small Cell Lung Cancer

February 14th 2022

Available treatment options as second-line therapy for small cell lung cancer.

ODAC Recommends New Trial Data of Sintilimab in US Population of Frontline NSCLC

February 10th 2022

The FDA’s Oncologic Drugs Advisory Committee voted against using single-country foreign data to support a biologics license application for sintilimab injection plus pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer.

Efforts to Effectively Target Rare Oncogenes Propel Progress in Lung Cancer

February 10th 2022

With 9 approved markers in non–small cell lung cancer and a plethora of established and emerging therapies that have been designed to target them, the need for molecular testing is more important than ever.

Distinct Genomic Profile of Lung Cancer in Never Smokers Comes Into Focus

February 10th 2022

A growing recognition of the distinct clinical, pathological, and biological features of lung cancers that arise in nonsmokers is fostering greater interest in examining the molecular underpinnings of lung cancer in this patient subset.

Dr. Bazhenova on Questions With Trastuzumab Deruxtecan in HER2-Mutated Lung Cancer

February 9th 2022

Lyudmila A. Bazhenova, MD, discusses future research questions with fam-trastuzumab deruxtecan-nxki in HER2-mutated lung cancer.

Dr. Basu Roy on the Challenges of Interpreting Molecular Testing Results in Lung Cancer

February 8th 2022

Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.

Emerging TKIs Shake Up the Treatment Landscape for EGFR Exon 20 Insertion+ NSCLC

February 8th 2022

Lyudmila Bazhenova, MD, explores key challenges faced with diagnosing and appropriately treating patients with non–small cell lung cancer that harbors EGFR exon 20 insertion mutations and provides insight into the second-line options that have recently garnered regulatory approval.

Neoadjuvant Immunotherapy Proving to Be Effective, Safe Option in Lung Cancer

February 8th 2022

Checkpoint inhibitors are often used in the advanced stage, but Erin A. Gillaspie, MD, MPH, argues that the data show physicians should consider utilizing this class of agents earlier in treatment.

Institutional Perspectives in Cancer- Lung Cancer: Chaired by Jason Porter, MD

February 8th 2022